Cathepsin S Causes Inflammatory Pain via Biased Agonism of PAR2 and TRPV4*
暂无分享,去创建一个
Erik Lindström | Peter McIntyre | Nigel W. Bunnett | P. McIntyre | S. Vanner | N. Bunnett | E. Lindström | V. Baraznenok | N. Veldhuis | W. Liedtke | Peishen Zhao | Nicholas Barlow | Nicholas A. Veldhuis | TinaMarie Lieu | Vera Baraznenok | Silvia Sostegni | Dane D. Jensen | C. Korbmacher | Silvia Sostegni | Silke Haerteis | Christoph Korbmacher | Wolfgang Liedtke | Stephen J. Vanner | N. Barlow | Matthew Metcalf | Martina Kocan | Ian Henderson | Raquel Guerrero-Alba | Eduardo E. Valdez-Morales | M. Kočan | S. Haerteis | D. Jensen | R. Guerrero-Alba | E. Valdez-Moráles | P. Zhao | Matthew C. Metcalf | T. Lieu | E. Lindström | Ian Henderson | Eduardo E. Valdez-Moráles
[1] T. Yaksh,et al. Quantitative assessment of tactile allodynia in the rat paw , 1994, Journal of Neuroscience Methods.
[2] R. Mullins,et al. β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2 , 2000, The Journal of cell biology.
[3] L. Devi,et al. Inflammatory Mediators Regulate Cathepsin S in Macrophages and Microglia: A Role in Attenuating Heparan Sulfate Interactions , 1999, Molecular medicine.
[4] O. Sasso,et al. Cathepsin S release from primary cultured microglia is regulated by the P2X7 receptor , 2010, Glia.
[5] S. Bevan,et al. Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain , 2007, Proceedings of the National Academy of Sciences.
[6] S. Coughlin,et al. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[7] G. Cottrell,et al. Trypsin IV, a Novel Agonist of Protease-activated Receptors 2 and 4* , 2004, Journal of Biological Chemistry.
[8] Arthur Christopoulos,et al. Signalling bias in new drug discovery: detection, quantification and therapeutic impact , 2012, Nature Reviews Drug Discovery.
[9] D. Bernstein,et al. Delayed Onset of Inflammation in Protease-Activated Receptor-2-Deficient Mice1 , 2000, The Journal of Immunology.
[10] J. Friedman,et al. Abnormal osmotic regulation in trpv4-/- mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[11] Ligong Liu,et al. An antagonist of human protease activated receptor‐2 attenuates PAR2 signaling, macrophage activation, mast cell degranulation, and collagen‐induced arthritis in rats , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[12] M. Malcangio,et al. The Liberation of Fractalkine in the Dorsal Horn Requires Microglial Cathepsin S , 2009, The Journal of Neuroscience.
[13] H. Samaratunga,et al. Kallikrein-related Peptidase 4 (KLK4) Initiates Intracellular Signaling via Protease-activated Receptors (PARs) , 2008, Journal of Biological Chemistry.
[14] E. Diamandis,et al. Proteinase-activated Receptors, Targets for Kallikrein Signaling* , 2006, Journal of Biological Chemistry.
[15] O. Schilling,et al. Proteomic identification of protease cleavage sites characterizes prime and non-prime specificity of cysteine cathepsins B, L, and S. , 2011, Journal of proteome research.
[16] J. d'Alayer,et al. Pseudomonas aeruginosa elastase disables proteinase-activated receptor 2 in respiratory epithelial cells. , 2005, American journal of respiratory cell and molecular biology.
[17] Yi Dai,et al. Sensitization of TRPA1 by PAR2 contributes to the sensation of inflammatory pain. , 2007, The Journal of clinical investigation.
[18] M. Steinhoff,et al. Role for protease activity in visceral pain in irritable bowel syndrome. , 2007, The Journal of clinical investigation.
[19] C. Wahlestedt,et al. Molecular cloning of a potential proteinase activated receptor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[20] M. Hollenberg,et al. Trypsin IV or Mesotrypsin and p23 Cleave Protease-activated Receptors 1 and 2 to Induce Inflammation and Hyperalgesia* , 2007, Journal of Biological Chemistry.
[21] N. Lambert,et al. The Bile Acid Receptor TGR5 Does Not Interact with β-Arrestins or Traffic to Endosomes but Transmits Sustained Signals from Plasma Membrane Rafts* , 2013, The Journal of Biological Chemistry.
[22] J. Pin,et al. Interaction of Protease-Activated Receptor 2 with G Proteins and β-Arrestin 1 Studied by Bioluminescence Resonance Energy Transfer , 2013, Front. Endocrinol..
[23] N. Bunnett,et al. Proteolytic activation of the epithelial sodium channel (ENaC) by the cysteine protease cathepsin-S , 2012, Pflügers Archiv - European Journal of Physiology.
[24] N. Bunnett,et al. Trafficking of Proteinase-activated Receptor-2 and β-Arrestin-1 Tagged with Green Fluorescent Protein , 1999, The Journal of Biological Chemistry.
[25] J. Wallace,et al. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism , 2000, Nature Medicine.
[26] Jennifer L. Harris,et al. Cellular Localization of Membrane-type Serine Protease 1 and Identification of Protease-activated Receptor-2 and Single-chain Urokinase-type Plasminogen Activator as Substrates* , 2000, The Journal of Biological Chemistry.
[27] J. Madon,et al. Protease‐activated receptor‐1 cleaved at R46 mediates cytoprotective effects , 2012, Journal of thrombosis and haemostasis : JTH.
[28] J. Griffin,et al. Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46. , 2012, Blood.
[29] J. Wallace,et al. A major role for proteolytic activity and proteinase-activated receptor-2 in the pathogenesis of infectious colitis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[30] S. Bevan,et al. Role of the cysteine protease cathepsin S in neuropathic hyperalgesia , 2007, PAIN.
[31] W. Krajewska,et al. Transient Receptor Potential Vanilloid 4 blockade protects against experimental colitis in mice: a new strategy for inflammatory bowel diseases treatment? , 2012, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.
[32] P. McNaughton,et al. Activation of the TRPV4 Ion Channel Is Enhanced by Phosphorylation , 2009, The Journal of Biological Chemistry.
[33] A. Kuliopulos,et al. Matrix metalloproteases and PAR1 activation. , 2011, Blood.
[34] Roy Jones,et al. Evidence for the activation of PAR‐2 by the sperm protease, acrosin: expression of the receptor on oocytes , 2000, FEBS letters.
[35] M. Hollenberg,et al. Neutrophil Elastase and Proteinase-3 Trigger G Protein-biased Signaling through Proteinase-activated Receptor-1 (PAR1)* , 2013, The Journal of Biological Chemistry.
[36] M. Hollenberg,et al. Proteinase-activated receptor-2 and human lung epithelial cells: disarming by neutrophil serine proteinases. , 2003, American journal of respiratory cell and molecular biology.
[37] M. Dalrymple,et al. Enhanced BRET Technology for the Monitoring of Agonist-Induced and Agonist-Independent Interactions between GPCRs and β-Arrestins , 2011, Front. Endocrin..
[38] D. Payan,et al. Mast cell tryptase regulates rat colonic myocytes through proteinase-activated receptor 2. , 1997, The Journal of clinical investigation.
[39] V. Trivedi,et al. Platelet Matrix Metalloprotease-1 Mediates Thrombogenesis by Activating PAR1 at a Cryptic Ligand Site , 2009, Cell.
[40] J. Hoxie,et al. Interactions of Mast Cell Tryptase with Thrombin Receptors and PAR-2* , 1997, The Journal of Biological Chemistry.
[41] D. Cohen,et al. Transient receptor potential vanilloid 4 mediates protease activated receptor 2-induced sensitization of colonic afferent nerves and visceral hyperalgesia. , 2008, American journal of physiology. Gastrointestinal and liver physiology.
[42] A. Zijlstra,et al. The membrane-anchored serine protease, TMPRSS2, activates PAR-2 in prostate cancer cells. , 2005, The Biochemical journal.
[43] Francesco Leonetti,et al. Substrate Profiling of Cysteine Proteases Using a Combinatorial Peptide Library Identifies Functionally Unique Specificities* , 2006, Journal of Biological Chemistry.
[44] M. Malcangio,et al. Microglial signalling mechanisms: Cathepsin S and Fractalkine , 2012, Experimental Neurology.
[45] A. Basbaum,et al. Proteinase-activated receptor-2 and hyperalgesia: A novel pain pathway , 2001, Nature Medicine.
[46] M. Steinhoff,et al. Proteinase‐activated receptor‐2 in human skin: tissue distribution and activation of keratinocytes by mast cell tryptase , 1999, Experimental dermatology.
[47] D. Payan,et al. Mechanisms of Desensitization and Resensitization of Proteinase-activated Receptor-2* , 1996, The Journal of Biological Chemistry.
[48] N. Bunnett,et al. Protease-activated receptors: contribution to physiology and disease. , 2004, Physiological reviews.
[49] S. Coughlin,et al. Molecular cloning, expression and potential functions of the human proteinase-activated receptor-2. , 1996, The Biochemical journal.
[50] J. Levine,et al. Protease‐activated receptor 2 sensitizes the transient receptor potential vanilloid 4 ion channel to cause mechanical hyperalgesia in mice , 2007, The Journal of physiology.
[51] Silvia Amadesi,et al. Protease-activated Receptor 2 (PAR2) Protein and Transient Receptor Potential Vanilloid 4 (TRPV4) Protein Coupling Is Required for Sustained Inflammatory Signaling* , 2013, The Journal of Biological Chemistry.
[52] M. Hollenberg,et al. 2-Furoyl-LIGRLO-amide: A Potent and Selective Proteinase-Activated Receptor 2 Agonist , 2004, Journal of Pharmacology and Experimental Therapeutics.
[53] E. Mayer,et al. Protease-Activated Receptor 2 Sensitizes the Capsaicin Receptor Transient Receptor Potential Vanilloid Receptor 1 to Induce Hyperalgesia , 2004, The Journal of Neuroscience.
[54] E. Lerner,et al. Cathepsin S Signals via PAR2 and Generates a Novel Tethered Ligand Receptor Agonist , 2014, PloS one.
[55] Michel Bouvier,et al. Real-time monitoring of receptor and G-protein interactions in living cells , 2005, Nature Methods.
[56] M. Hollenberg,et al. Neutrophil Elastase Acts as a Biased Agonist for Proteinase-activated Receptor-2 (PAR2)* , 2011, The Journal of Biological Chemistry.
[57] M. Bogyo,et al. Cathepsin S is activated during colitis and causes visceral hyperalgesia by a PAR2-dependent mechanism in mice. , 2011, Gastroenterology.
[58] S. Coughlin,et al. Agonist Recognition by Proteinase-activated Receptor 2 and Thrombin Receptor , 1996, The Journal of Biological Chemistry.
[59] A. Denadai-Souza,et al. Role of transient receptor potential vanilloid 4 in rat joint inflammation. , 2012, Arthritis and rheumatism.
[60] V. Turk,et al. Expression and activity profiling of selected cysteine cathepsins and matrix metalloproteinases in synovial fluids from patients with rheumatoid arthritis and osteoarthritis , 2010, Biological chemistry.
[61] F. Cattaruzza,et al. A role for transient receptor potential vanilloid 4 in tonicity‐induced neurogenic inflammation , 2010, British journal of pharmacology.
[62] H. Samaratunga,et al. Prostatic trypsin-like kallikrein-related peptidases (KLKs) and other prostate-expressed tryptic proteinases as regulators of signalling via proteinase-activated receptors (PARs) , 2008, Biological chemistry.
[63] J Y Suen,et al. Modulating human proteinase activated receptor 2 with a novel antagonist (GB88) and agonist (GB110) , 2012, British journal of pharmacology.
[64] A. Agarwal,et al. PAR1 Is a Matrix Metalloprotease-1 Receptor that Promotes Invasion and Tumorigenesis of Breast Cancer Cells , 2005, Cell.
[65] G. Mize,et al. Prostate-Specific Kallikreins-2 and -4 Enhance the Proliferation of DU-145 Prostate Cancer Cells through Protease-Activated Receptors-1 and -2 , 2008, Molecular Cancer Research.